Q32 Bio to take Homology Medicines' Nasdaq spot to fund PhII trials in autoimmune, inflammatory conditions
The reverse mergers are flowing. Q32 Bio will take Homology Medicines’ place on the Nasdaq, the companies said Thursday morning, and the…
Source: biztoc.com